Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883802 | 1.00 | FKBP1A (0.47) | FKBP1ASPHK1 | |
| SCHEMBL5492839 | 1.00 | FKBP1A (0.47) | FKBP1ASPHK1 | |
| SCHEMBL7048968 | 0.95 | ACE (0.50) | FKBP1A | |
| SCHEMBL6883743 | 0.93 | FKBP1A (0.49) | FKBP1ASPHK1 | |
| SCHEMBL5497995 | 0.93 | FKBP1A (0.49) | FKBP1ASPHK1 | |
| SCHEMBL5497998 | 0.93 | FKBP1A (0.49) | FKBP1ASPHK1 | |
| SCHEMBL16116984 | 0.90 | SPHK1 (0.48) | FKBP1ASPHK1 | |
| SCHEMBL16116973 | 0.90 | SPHK1 (0.48) | FKBP1ASPHK1 | |
| SCHEMBL4186745 | 0.88 | FKBP1A (0.46) | FKBP1A | |
| SCHEMBL5496862 | 0.88 | FKBP1A (0.53) | FKBP1ASPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | claimed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | claimed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | claimed |
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | FKBP1A 203/4885SPHK1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.